CRyo-Ablation to Treat Patients With HOCM.

NCT01875016 | Unknown

• 1 other identifier: CRASH
• Study Type: interventional
• Target: 15
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of the study is to perform endocardial catheter CRyo-Ablation to relieve the LVOT obstruction in patients with Hypertrophic Obstructive Cardiomyopathy. The investigators hypothesize that the investigators will be able to reduce \> 50% of the initial LVOT gradient. This will be considered as a successful procedure.

Conditions

HOCM, Hypertrophic Obstructive Cardiomyopathy

Keywords

Cryo ablation; Cardiomyopathy

Outcome Measures

Primary Outcomes (1)

• Acute and long term reduction of initial LVOT gradient

  Post procedure and up to 12 months follow up

Secondary Outcomes (1)

• Number of patients with procedure related complications.

  During the procedure untill discharge.

Interventions

CRyo-Ablation to Treat HOCM. PROCEDURE

CRyo-Ablation to Treat Patients With HOCM.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient must be ≥18 years of age
• The patient has left ventricular outflow tract obstruction with hypertrophic obstructive cardiomyopathy
• The patient is on optimal medication
• The patient is not eligible for/failed/refused alcohol ablation
• The patient is not eligible for/failed/refused myectomy
• The patient is willing to participate in the study and has signed informed consent
• The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved be the appropriate medical ethics committee.

You may not qualify if:

• Pregnant or nursing patients Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test
• Patient has history of or known impaired renal function (Serum creatinine \>2.0 mg/dL or 177 µmol/l) or on dialysis
• Patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated
• Patient has a known hypersensivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel and/or contrast sensitivity/allergy that cannot be adequately pre-medicated
• Patient has other medical illness not related to the hypertrophic cardiomyopathy (e.g., cancer, known malignancy, or cognitive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than 1 year)
• Subject is enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by the investigator, during the course of this clinical study
• Subject is anticipated not being able to complete the study

Sponsors & Collaborators

• Shaare Zedek Medical Center: lead
• Medtronic: collaborator

Related Publications (2)

• Keane D, Hynes B, King G, Shiels P, Brown A. Feasibility study of percutaneous transvalvular endomyocardial cryoablation for the treatment of hypertrophic obstructive cardiomyopathy. J Invasive Cardiol. 2007 Jun;19(6):247-51.

  PMID: 17541123 BACKGROUND

• Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, Meyer Zu Vilsendorf D, Schloesser M, Beer G, Lieder F, Stellbrink C, Kuhn H. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. J Am Coll Cardiol. 2011 Feb 1;57(5):572-6. doi: 10.1016/j.jacc.2010.07.055.

  PMID: 21272748 BACKGROUND

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic; Cardiomyopathies

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of EP Unit

Study Record Dates

• First Submitted: June 4, 2013
• First Posted: June 11, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2014
• Study Completion: April 1, 2015
• Last Updated: June 11, 2013

Record last verified: 2013-06